Home › Metastatic Cancer › NCT06896162
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
In order to participate in this study a subject must meet all of the eligibility criteria outlined below. Inclusion Criteria * Written informed consent was obtained to participate in the study and HIPAA authorization for release of personal health information. * Subjects are willing and able to comply with study procedures based on the judgment of the investigator. * Age ≥ 18 years at the time of consent. * ECOG or Karnofsky Performance Status of 0-2. * Documented Stage IV solid tumor malignancy: NSCLC, CRC, Breast or Bladder Cancer * The treating provider deems Next Generation Sequencing (NGS) testing appropriate and plans to consider results in either first- or second-line therapy in the metastatic setting * A genomic tumor test has not been ordered or has been ordered but not resulted. Exclusion Criteria: • Subjects with an active concurrent malignancy.
About the study
This is a hybrid decentralized, single-arm, interventional study designed to evaluate the impact of precision medicine navigation and reflexive expert review of next-generation sequencing (NGS) for patients with stage IV solid tumor malignancies (breast, lung, colorectal, and bladder cancers).
The purpose of this study is to investigate whether intervention from a centralized precision oncology navigator and expert review of NGS results by the precision oncology pharmacist will increase ordering of Level 1/2 genome informed therapy (GIT) compared to an estimated historical rate of 15%. Secondary endpoints will assess the impact of a centralized precision oncology navigator and expert review of NGS results on enrollment in biomarker-directed clinical trials and overall survival at 2 years after return of NGS results. The study will take approximately 12 months for enrolment and 2 years of follow-up after the date of NGS results.
What is being tested
- Expert Review (other)
- Blood or tissue samples collection. (other)
- The Precision Oncology Navigation (other)
Sponsor: UNC Lineberger Comprehensive Cancer Center · Participants: 500 · Started: Jun 27, 2025
Contact the study team
- Stephanie Drotts · Phone: 919-445-4872
- Douglas Kirk · Phone: 919-445-6240
Official record on ClinicalTrials.gov — NCT06896162
Locations in the U.S.
| North Carolina | Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.